Latest Articles
Cell map offers insights into endometrial dysfunction in women with PCOS - MSN
Cell map offers insights into endometrial dysfunction in women with PCOS MSN
Published: Jan. 10, 2026, 2:52 a.m.
I spent £10,000 to treat my endometriosis – we don’t need more NHS hurdles - MSN
I spent £10,000 to treat my endometriosis – we don’t need more NHS hurdles MSN
Published: Jan. 9, 2026, 5:35 p.m.
Could UK Workers Ever Get Paid Period Leave? - HuffPost UK
Could UK Workers Ever Get Paid Period Leave? HuffPost UK
Published: Jan. 9, 2026, 3:44 p.m.
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com UK
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com UK
Published: Jan. 9, 2026, 2:25 p.m.
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com
Published: Jan. 9, 2026, 1:59 p.m.
NHS online hospital to focus on nine conditions – including prostate, menstrual and eye problems - PublicTechnology
NHS online hospital to focus on nine conditions – including prostate, menstrual and eye problems PublicTechnology
Published: Jan. 9, 2026, 11:44 a.m.
Endometriosis Treatment Market Forecast to Grow to USD 3.37 - openPR.com
Endometriosis Treatment Market Forecast to Grow to USD 3.37 openPR.com
Published: Jan. 9, 2026, 10:57 a.m.
New NHS online hospital to focus on eyes, menopause and prostates - AOL.com
New NHS online hospital to focus on eyes, menopause and prostates AOL.com
Published: Jan. 9, 2026, 8:39 a.m.
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …
Published: Jan. 9, 2026, 6:18 a.m.
Burlesque class helping women boost confidence and body positivity - News & Star
Burlesque class helping women boost confidence and body positivity News & Star
Published: Jan. 9, 2026, 5 a.m.
Link copied to clipboard!